IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia

Cancer Letters

Volumn 231, Issue 2, 2006, Pages 309-313

  Matsumoto, Koji ^a   Yasugi, Toshiharu ^a   Oki, Akinori ^b   Fujii, Takuma ^c   Nagata, Chisato ^d   Sekiya, Souei ^e   Hoshiai, Hiroshi ^f   Taketani, Yuji ^a   Kanda, Tadahito ^g   Kawana, Takashi ^h   Yoshikawa, Hiroyuki ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d GIFU UNIVERSITY   (Japan)

^e CHIBA UNIVERSITY   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^h TEIKYO UNIVERSITY   (Japan)

Author keywords

CIN; HPV; L1 capsids; Regression; VLP

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; TUMOR MARKER; VIRUS DNA;

ARTICLE; CANCER GRADING; CANCER REGRESSION; COHORT ANALYSIS; CONDYLOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; UNIVARIATE ANALYSIS; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CAPSID; WART VIRUS;

ANTIBODIES, VIRAL; CAPSID; CAPSID PROTEINS; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; DNA, VIRAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; NEOPLASM REGRESSION, SPONTANEOUS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL PROTEINS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPES; MIRIDAE;

EID: 29844441096     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.02.023     Document Type: Article

References (30)

1. D.M. Parkin Global cancer statistics in the year 2000 Lancet Oncol. 2 2001 533 543
2. A.G. Ostor Natural history of cervical intraepithelial neoplasia: a critical review Int. J. Gynecol. Pathol. 12 1993 186 192
3. H. zur Hausen Papillomaviruses and cancer: from basic studies to clinical application Nat. Rev. Cancer 2 2002 342 350
4. I.H. Frazer Prevention of cervical cancer through papillomavirus vaccination Nat. Rev. Immunol. 4 2004 46 54
5. J. Dillner The serological response to papillomaviruses Semin. Cancer Biol. 9 1999 423 430
6. M. Nakagawa, R. Viscidi, I. Deshmukh, M.D. Costa, J.M. Palefsky, S. Farhat, and A.B. Moscicki Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women Clin. Diagn. Lab. Immunol. 9 2002 877 882
7. T. Luostarinen, V.A.F. Geijersstam, T. Bjørge, C. Eklund, M. Hakama, and T. Hakulinen No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11 Int. J. Cancer 80 1999 818 822
8. I. Silins, Z. Wang, E. Åvall-Lundqvist, B. Frankendal, U. Vikmanis, and M. Sapp Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis J. Gen. Virol. 80 1999 2931 2936
9. H. Yoshikawa, C. Nagata, K. Noda, S. Nozawa, A. Yajima, and S. Sekiya Human papillomavirus infection and other risk factors for cervical intraepithelial neoplasia in Japan Br. J. Cancer 80 1999 621 624
10. M. Yokoyama, T. Iwasaka, C. Nagata, S. Nozawa, S. Sekiya, and Y. Hirai Prognostic factors associated with the clinical outcome of cervical intraepithelial neoplasia: a cohort study in Japan Cancer Lett. 192 2003 171 179
11. H. Yoshikawa, T. Kawana, M. Kitagawa, M. Mizuno, H. Yoshikura, and A. Iwamoto Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers Jpn. J. Cancer Res. 82 1991 524 531
12. H. Nagano, H. Yoshikawa, T. Kawana, H. Yokota, Y. Taketani, and H. Igarashi Association of multiple human papillomavirus types with vulvar neoplasias J. Obstet. Gynecol. Res. 22 1996 1 8
13. K. Matsumoto, H. Yoshikawa, Y. Taketani, K. Yoshiike, and T. Kanda Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females Jpn. J. Cancer Res. 88 1997 369 375
14. K. Matsumoto, H. Yoshikawa, T. Yasugi, S. Nakagawa, K. Kawana, and A. Takeoka IgG antibodies to human papillomavirus 16, 52, 58 and 6 L1 capsids: case-control study of cervical intraepithelial neoplasia in Japan J. Med. Virol. 69 2003 441 446
15. K. Matsumoto, T. Yasugi, A. Oki, H. Hoshiai, Y. Taketani, T. Kawana, and H. Yoshikawa Are smoking and chlamydial infection risk factors for CIN? Different results after adjustment for HPV DNA and antibodies Br. J. Cancer 89 2003 831 833
16. R.G. Hoffmann Statistics in the practice of medicine J. Am. Med. Assoc. 185 1963 864 873
17. J.K. Chan, B.J. Monk, C. Brewer, K.A. Keefe, K. Osann, and S. McMeekin HPV infection number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3 Br. J. Cancer 89 2003 1062 1066
18. N.F. Schlecht, R.W. Platt, E. Duarte-Franco, M.C. Costa, J.P. Sobrinho, and J.C.M. Prado Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia J. Natl Cancer Inst. 95 2003 1336 1343
19. T.D. de Gruijl, H.J. Bontkes, J.M.M. Walboomers, J.T. Schiller, M.J. Stukart, and B.S. Groot Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia J. Natl Cancer Inst. 89 1997 630 638
20. R. Kirnbauer, L.M. Chandrachud, B.W. O'Neil, E.R. Wagner, G.J. Grindlay, and A. Armstrong Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization Virology 219 1996 37 44
21. B. Nonnenmacher, N.L. Hubbert, R. Kirnbauer, K.V. Shah, N. Munoz, and F.X. Bosch Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain J. Infect. Dis. 172 1995 19 24
22. L. Wideroff, M. Schiffman, P. Hinderer, A. Armstrong, C.E. Greer, and M.M. Manos Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions J. Infect. Dis. 180 1999 1424 1428
23. M.C. Wolkers, N. Brouwenstijn, A.H. Bakker, M. Toebes, and T.N. Schumacher Antigen bias in T cell cross-priming Science 304 2004 1314 1317
24. K. Matsumoto, G.R. Leggatt, J. Zhong, X. Liu, R.L. de Kluyver, and T. Peters Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors J. Natl Cancer Inst. 96 2004 1611 1619
25. A.S. Kadish, G.Y. Ho, R.D. Burk, Y. Wang, S.L. Romney, R. Ledwidge, and R.H. Angeletti Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia J Natl Cancer Inst. 89 1997 1285 1293
26. T.D. de Gruijl, H.J. Bontkes, J.M.M. Walboomers, M.J. Stukart, A.A.J.P. Robbesom, and B.M.E. von Blomberg-van der Filer Analysis of IgG reactivity against human papillomavirus type-16 E7 in patients with cervical intraepithelial Int. J. Cancer 68 1996 731 738
27. K. Matsumoto, H. Yoshikawa, T. Yasugi, S. Nakagawa, K. Kawana, and S. Nozawa Balance of IgG subclasses toward human papillomavirus type 16 (HPV16) L1-capsids is a possible predictor for the regression of HPV16-positive cervical intraepithelial neoplasia Biochem. Biophys. Res. Commun. 258 1999 128 131
28. Z.H. Wang, L. Kjellberg, H. Abdalla, F. Wiklund, C. Eklund, and P. Knekt Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids J. Infect. Dis. 181 2000 456 462
29. R. Höpfl, K. Heim, N. Christensen, K. Zumbach, U. Wieland, and B. Volgger Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7 Lancet 356 2000 1985 1986
30. A.S. Kadish, P. Timmins, Y. Wang, G.Y.F. Ho, R.D. Burk, and J. Ketz Albert Einstein cervix dysplasia clinical consortium regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide Cancer Epidemiol. Biomarkers Prev. 11 2002 483 488